Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Oral contraceptives may prevent ovarian cancer in BRCA1 and BRCA2 mutation carriers. Parity shows a reduced risk for BRCA1 carriers but an increased risk for BRCA2 carriers, warranting further investigation.
Area Of Science
- Gynecology
- Oncology
- Genetics
Background
- Ovarian cancer risk is linked to ovulation and menstrual cycle factors like parity, breastfeeding, and oral contraceptive use.
- BRCA1 and BRCA2 gene mutations significantly increase ovarian cancer risk.
- Investigating reproductive factors in mutation carriers is crucial for risk assessment and prevention strategies.
Purpose Of The Study
- To evaluate the impact of oral contraceptive use, parity, breastfeeding, and tubal ligation on ovarian cancer risk.
- To specifically assess these factors in women with BRCA1 or BRCA2 mutations.
- To identify potential preventive measures for ovarian cancer in high-risk individuals.
Main Methods
- A matched case-control study design was employed.
- Participants included women with BRCA1/BRCA2 mutations, with and without ovarian cancer, matched for birth year, residence, mutation type, and breast cancer history.
- Reproductive history was collected via questionnaires, and odds ratios were calculated.
Main Results
- Oral contraceptive use was associated with a reduced risk of ovarian cancer in both BRCA1 (OR 0.56) and BRCA2 (OR 0.39) mutation carriers.
- Parity showed a reduced risk in BRCA1 carriers (OR 0.67) but an increased risk in BRCA2 carriers (OR 2.74).
- Breastfeeding reduced risk in BRCA1 carriers (OR 0.74), with a similar non-significant trend in BRCA2 carriers. Tubal ligation showed no significant association.
Conclusions
- Oral contraceptives represent a potential preventive strategy for ovarian cancer in BRCA1 and BRCA2 mutation carriers.
- The potential adverse effect of parity on ovarian cancer risk in BRCA2 mutation carriers requires further research.
- Understanding reproductive factor impacts can inform personalized risk management for BRCA mutation carriers.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Nondisjunction is the failure of homologous chromosomes or sister chromatids to separate correctly and move to the opposite poles of the cells. This produces daughter cells with abnormal chromosome numbers. Nondisjunction is common during anaphase I or anaphase II of meiosis. Mutations in synaptonemal complex proteins that attach homologous chromosomes increase the chances of nondisjunction in anaphase I of meiosis I. In contrast, mutations in topoisomerases and condensins that hold...
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...